Analyst Notes: Diabetologists speak out on market access challenges for leading oral treatments for diabetes

US physicians, it would seem, have to work much harder to get the oral treatments they want for their diabetes patients. Market barriers influence close to 40 percent of prescriptions, which is almost double the impact in Europe. What's driving this huge Atlantic divide?

Two reports out from FirstView examine the way market barriers such as, cost, market access, patient preferences, guidelines and recommendations, and more, affect the way diabetologists and primary care physicians in the US and the EU5 countries (France, Germany, Italy, Spain and the UK) prescribe oral treatments for type 2 diabetes mellitus.

FirstView's Market Access Impact: Type 2 Diabetes Mellitus (Orals) 2017 reports for the US and EU5 cover up to 9 type 2 diabetes mellitus brands from leading diabetes players including AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck & Co., Johnson & Johnson and Takeda.

The reports show how seven different market barriers affect each brand's market share, and reveal which competitors each brand loses share to, and takes it from. Companies can download the reports directly from FirstView, saving them the time and expense of commissioning bespoke research.

Insights, Analysis & Views

There seems to be a big barrier problem in the US, where physicians claim that close to 40 percent of all oral diabetes therapy prescriptions are impacted by barriers. Perhaps an odd thing to say in light of physician usage rates for some leading brands coming in over 90 percent?

Maybe not when you consider the impact of one particular barrier, which 35 percent to 60 percent of surveyed doctors experience across all brands. Are other things at play? Another barrier impacts 25 percent to 55 percent of prescriptions, and market access mistakes could be the key reason. Suffice to say, things are rosy for one brand, even with all these restrictions. In a barrier free world, one brand would lose out…big time. If restrictions were lifted, physicians predict usage could plummet.

In Europe, where prescription barriers have a lower impact compared to the US, the pain is still being felt by some brands. Of the 9 brands included in the survey, 8 lose market share. Interestingly, cost isn't the biggest barrier. While treatment costs do have an impact on prescribing patterns, four other barriers have the same or more of an impact; find out what they are. In light of this, understanding the fine margins could be the difference. The overall barrier impact in EU5 markets is smaller compared to the US, but knowing what commercial levers to pull could make all the difference.

Full reports available from FirstView

These and many other insights, along with the full survey results are available from the FirstView web site.

Interested parties can purchase and download FirstView Market Access Impact: Type 2 Diabetes Mellitus (Orals) 2017 for the US and EU5 markets directly from the FirstView reports store. Or contact FirstView for more information by calling +1 212-220-0880 or +44(0)20.7665.9240

To read more Analyst Notes articles, click here.